@article{50a611a121f54ba893ba5aa0af61e2b8,
title = "CAR-T failure: beyond antigen loss and T cells",
author = "Paolo Strati and Neelapu, {Sattva S.}",
note = "Funding Information: Conflict-of-interest disclosure: S.S.N. served as an advisory board member or consultant for Kite a Gilead Company, Merck, Bristol-Myers Squibb, Novartis, Celgene, Pfizer, Allogene Therapeutics, Cell Medica/Kuur, Incyte, Precision Biosciences, Legend Biotech, Adicet Bio, Calibr, Unum Therapeutics, and Bluebird Bio; received research support from Kite a Gilead Company, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene Therapeutics, Precision Biosciences, and Acerta; received royalties from Takeda Pharmaceuticals; and has intellectual property related to cell therapy. P.S. declares no competing financial interests.",
year = "2021",
month = may,
day = "13",
doi = "10.1182/blood.2020010462",
language = "English (US)",
volume = "137",
pages = "2567--2568",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",
}